A rigorous process

The process for biosimilar medicine development involves rigorous analytical studies to establish a comprehensive understanding of the similarity of the biosimilar to the reference product. Assessments of toxicity and clinical studies are also used to further establish similarity. Ultimately, the goal is to demonstrate that there are no clinically meaningful differences between the reference product and the biosimilar based on the findings from all of these studies.

Building on the established
clinical profile of the
reference biologic.

Using multiple state-of-the-art-methods, protein structures can be extensively characterized so that the reference product and biosimilar can be directly compared, helping to ensure comparability of both functional integrity and performance in vivo. These comparisons, with respect to the structure and function of the molecule, will provide the foundation for development, which builds on the clinical experience with the reference biologic.

Biosimilar development requires substantial time and financial investment

Development of biosimilar medicines begins with substantial investment in the specialized infrastructure, expertise, and technology required to create the product, verify that it is biosimilar, and ultimately to maintain quality production.

Investing in the future

While biosimilars have the potential to provide additional treatment options at lower cost, development of biosimilars requires significant investment. Development of a biosimilar may take 5 to 9 years at a cost of over $100 million, not including regulatory fees. A generic version of a small- molecule drug, on the other hand, costs $1 million to $2 million and takes approximately 2 years to develop.

Drug development comparison

Transitioning to value-based care? Learn How Biosimilars may help

You are now leaving Pfizer

Link to sites outside of Pfizer are provided as a resource to the viewer. Pfizer accepts no responsibility for the content of linked sites.